This listing of claims will replace all prior versions, and listings, of claims in the application.

***Listing of Claims***

1. ***(cancelled)***

2. ***(currently amended)*** A compound selected from the group consisting of:

a) 3-(3-aminomethyl-benzyl)-2-[2,2']bithiophenyl-5-yl-6-methoxy-3H-quinazolin-4-one,

b) 3-(3-aminomethyl-propyl)-2-[2,2']bithiophenyl-5-yl-6-chloro-3H-quinazolin-4-one, ~~and~~

c) 3-(3-aminomethyl-propyl)-2-[2,2;]bithiophenyl-5-yl-7-chloro-3H-quinazolin-4-one, and

a physiologically acceptable salt and solvate thereof.

3. ***(cancelled)***

4. ***(currently amended)*** A compound of the formula I



**I**

in which

R and $R^1$ are independently of each other H, A, OH, OA, $OCH_2$-Ar, Hal, $NH_2$, NHA, $NA_2$, $NO_2$, CN, $C(O)R^2$, $CONH_2$, CONHA, $CONA_2$, COOH, COOA or $SO_2A$,

$R^2$ is H,

$R^3$ H or $-C(=NH)-NH_2$,

$R^4$ is Ar, cycloalkyl, phenylalkyl or Het,

Y is absent or is alkenyl having 2 to 4 carbon atoms,

Z is absent or is phenylene,

A is unbranched or branched alkyl having 1 to 6 carbon atoms,

Ar is phenyl, naphthyl, biphenyl or benzofuranyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, $CF_3$, $OCF_3$, Hal, CN, COOH, COOA, $NH_2$, NHA, $NA_2$, $NO_2$, $SO_2NH_2$, $SO_2NAH$ or $SO_2NA_2$,

Het is a saturated, partially or completely unsaturated mono- or bicyclic heterocyclic radical and having 5 to 10 ring members, and having 1 or 2 N and/or 1 or 2 S or O atoms, which is optionally mono- or disubstituted by A, Hal, OH, OA, $CF_3$, $OCF_3$, $NH_2$, NHA, $NA_2$, COOH, COOA, phenyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, $CF_3$, $OCF_3$, Hal, CN, COOH, COOA, $NH_2$, NHA, $NA_2$, $NO_2$, $SO_2NH_2$, $SO_2NAH$ or $SO_2NA_2$, ~~or~~ thiophenyl**, or bithiophenyl,** which **latter two groups are** ~~is~~ unsubstituted or mono-, di- or trisubstituted by A, OH, OA, $CF_3$, $OCF_3$, Hal, CN, COOH, COOA, $NH_2$, NHA, $NA_2$, $NO_2$, $SO_2NH_2$, $SO_2NAH$ or $SO_2NA_2$,

Hal is F, Cl, Br or I,

n is 1, 2 or 3, and

m is 0, 1, 2 or 3,

with the proviso that

if Z and Y are absent, then $R^4$ is not phenylalkyl, **and**

**if Z and Y are absent, $R^4$ is phenyl or 4-methoxyphenyl, R, $R^1$, $R^2$ and $R^3$ are H, then the sum of n and m is not 2 or 3,**

or a pharmaceutically acceptable salt or solvate thereof.

5. ***(previously presented)*** A method of antagonizing glycoprotein IbIX, comprising administering to a patient in need thereof an effective amount of a compound according to claim 4, or a pharmaceutically acceptable salt or solvate thereof.

6. ***(previously presented)*** A method of controlling a thrombotic disorder and sequelae deriving therefrom, comprising

administering to a patient in need thereof an effective amount of a compound according to claim 4, or a pharmaceutically acceptable salt or solvate thereof.

7. ***(previously presented)*** A pharmaceutical composition comprising a compound according to Claim 4 or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable excipient.

8. ***(cancelled)***

9. ***(previously presented)*** A method for the prophylaxis and/or therapy of a thrombotic disorder comprising

administering to a patient in need thereof an effective amount of a compound according to claim 4, or a pharmaceutically acceptable salt or solvate thereof.

10. ***(cancelled)***

11. ***(cancelled)***

12. ***(previously presented)*** A method according to claim 6, wherein the sequelae is myocardial infarct, arteriosclerosis, angina pectoris, acute coronary syndrome, peripheral circulatory disorder, stroke, transient ischaemic attack, or reocclusion/restenosis after angioplasty/stent implantation.

13. ***(currently amended)*** A method of preventing adhesion of substances to a foreign surface **where said foreign surface comes into contact with a body,** ~~**inside a body**~~ comprising ~~**applying**~~ **the step of preparing a foreign surface comprising** a compound according to claim 4 ~~**onto said foreign surface**~~.

14. ***(currently amended)*** A method according to claim ~~**12**~~ **13**, wherein the foreign surface is an implant, catheter or heart pacemaker.

15. ***(previously presented)*** A compound according to claim 4, wherein $R^3$ is H.

16. ***(previously presented)*** A compound according to claim 4, wherein

R is H,

$R^1$ is H, A, OA or Hal,

$R^3$ is H,

$R^4$ is phenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 4-tert-butylphenyl, 4- dimethylaminophenyl, 4-methoxyphenyl, 3-methoxyphenyl, 3-chlorophenyl, 3,4,5-trimethoxyphenyl, 3,4-dimethoxyphenyl, 2,5-dimethoxyphenyl, 3',5'-dimethoxy-biphenyl-4-yl, 2',4'-dimethoxybiphenyl-4-yl, biphenyl-4-yl, naphthalen-1-yl, naphthalen-2-yl or benzofuran-5-yl, phenylethyl, cyclohexyl, 2-furyl, thiophen-2-yl, thiophen-3-yl, 5-(3,4-dimethoxyphenyl)-thiophen-2-yl or 5-[2,2']bithiophenyl,

Z is absent,

N is 1, and

m is 1.

17. ***(previously presented)*** A compound according to claim 4, wherein

R is H,

$R^1$ is H, A, OA or Hal,

$R^3$ is H,

$R^4$ is phenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 4-tert-butylphenyl, 4-dimethylaminophenyl, 4-methoxyphenyl, 3-methoxyphenyl, 3-chlorophenyl, 3,4,5-trimethoxyphenyl, 3,4-dimethoxyphenyl, 2,5-dimethoxyphenyl, 3',5'-dimethoxy-biphenyl-4-yl, 2',4'-dimethoxybiphenyl-4-yl, biphenyl-4-yl, naphthalen-1-yl, naphthalen-2-yl or benzofuran-5-yl, phenylethyl, cyclohexyl, 2-furyl, thiophen-2-yl, thiophen-3-yl, 5-(3,4-dimethoxyphenyl)-thiophen-2-yl or 5-[2,2']bithiophenyl,

Z is phenylene,

n is 1, and

m is 1.

18. ***(previously presented)*** A compound according to claim 4, wherein

R is H,

$R^1$ is H, A, OA or Hal,

$R^2$ is H,

$R^3$ is H,

Y is -CH-CH-,

$R^4$ is phenyl, 4-dimethylaminophenyl or 2,5-dimethoxyphenyl,

Z is absent,

n is 1, and

m is 1.

19. ***(previously presented)*** A compound according to claim 4, wherein

R is H,

$R^1$ is H, A, OA or Hal,

$R^3$ is H,

Y is -CH=CH-,

$R^4$ is phenyl, 4-dimethylaminophenyl or 2,5-dimethoxyphenyl,

Z is phenylene,

n is 1, and

m is 1.

20. ***(previously presented)*** A compound according to claim 4, wherein

R is H,

$R^1$ is H, A, OA or Hal,

$R^3$ is H,

Y is absent,

$R^4$ is phenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 4-tert-butylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, 3-chlorophenyl, 3,4,5-trimethoxyphenyl, 3,4-dimethoxyphenyl, 3',5'-dimethoxybiphenyl, 2',4'-

dimethoxybiphenyl-4-yl, biphenyl-4-yl, naphthalen-1-yl, naphthalen-2-yl or benzofuran-5-yl, phenylethyl, cyclohexyl, 2-furyl, thiophen-2-y], thiophen-3-yl, 5-(3,4-dimethoxyphenyl)-thiophen-2-yl or 5-[2,2']bithiophenyl,

Z is absent,

n is 1, and

m is 1.

21. ***(previously presented)*** A compound according to claim 4, wherein

R is H,

$R^1$ is H, A, OA or Hal,

$R^3$ is H,

Y is absent,

$R^4$ is phenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 4-tert-butylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, 3-chlorophenyl, 3,4,5-trimethoxyphenyl, 3,4-dimethoxyphenyl, $3^f$,5'-dimethoxybiphenyl-4-yl, 2',4'-dimethoxybiphenyl-4-yl, biphenyl-4-yl, naphthalen-1-yl, naphthalen-2-yl or benzofuran-5-yl, phenylethyl, cyclohexyl, 2-furyl, thiophen-2-yl, thiophen-3-yl, 5-(3,4-dimethoxyphenyl)-thiophen-2-yl or 5-[2,2']bithiophenyl,

Z is phenylene,

n is 1, and

m is 1.

22. ***(currently amended)*** A compound of formula I




I

in which

R and $R^1$ are, independently of each other, H, A, OH, OA, $OCH_2$-Ar, Hal, $NH_2$, NHA, $NA_2$, $NO_2$, CN, $C(O)R^2$, $CONH_2$, CONHA, $CONA_2$, COOH, COOA or $SO_2A$,

$R^2$ and $R^3$ are, independently of each other, H, A, or $C(=NH)-NH_2$,

$R^4$ is Ar, cycloalkyl, phenylalkyl or Het,

Y is absent,

Z is absent or is phenylene,

A is unbranched or branched alkyl having 1 to 6 carbon atoms,

Ar is phenyl, naphthyl, biphenyl or benzofuranyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, $CF_3$, $OCF_3$, Hal, CN, COOH, COOA, $NH_2$, NHA, $NA_2$, $NO_2$, $SO_2NH_2$, $SO_2NAH$ or $SO_2NA_2$,

Het is a saturated, partially or completely unsaturated mono- or bicyclic heterocyclic radical having 5 to 10 ring members, and having 1 or 2 N and/or 1 or 2 S or O atoms, which is optionally mono- or disubstituted by A, Hal, OH, OA, $CF_3$, $OCF_3$, $NH_2$, NHA, $NA_2$, COOH, COOA, phenyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, $CF_3$, $OCF_3$, Hal, CN, COOH, COOA, $NH_2$, NHA, $NA_2$, $NO_2$, $SO_2NH_2$, $SO_2NAH$ or $SO_2NA_2$, ~~or~~ thiophenyl**, or bithiophenyl,** which **latter two groups are** ~~is~~ unsubstituted or mono-, di- or trisubstituted by A, OH, OA, $CF_3$, $OCF_3$, Hal, CN, COOH, COOA, $NH_2$, NHA, $NA_2$, $NO_2$, $SO_2NH_2$, $SO_2NAH$ or $SO_2NA_2$,

Hal is F, Cl, Br or I,

n is 1, 2 or 3, and

m is 0, 1,2 or 3,

with the provisos that

if Z is absent, $R^4$ is phenyl, phenylalkyl, alkoxyphenyl or pyridyl, R is H and $R^1$ is **H or** $NH_2$, then $R^2$ and $R^3$ are not A,

**if Z and Y are absent, $R^4$ is phenyl or 4-methoxyphenyl, R, $R^1$, $R^2$ and $R^3$ are H, then the sum of n and m is not 2 or 3,** and

if Z is absent, then $R^4$ is not phenylalkyl,

or a pharmaceutically acceptable salt or solvate thereof.

23. ***(currently amended)*** A compound according to claim 22,

with the additional ~~provisos~~ **proviso** that

if Z is absent and $R^4$ is phenyl or 4-methoxyphenyl, then R is not H or 6-Cl, $R^1$ is not H or 8-Cl, $R^2$ is not H, methyl or ethyl, $R^3$ is not H, methyl or ethyl and the sum of n and m is not 2 or 3~~, and~~

~~if Z is absent, $R^4$ is phenyl or 4-methoxyphenyl, R, $R^1$, $R^2$ and $R^3$ are H, then the sum of n and m is not 2 or 3~~.

24. ***(previously presented)*** A compound according to claim 22, wherein

R is H, and

$R^1$ is H, A, OA or Hal.

25. ***(previously presented)*** A compound according to claim 22, wherein

R is H,

$R^1$ is H, A, OA or Hal, and

Z is absent.

26. ***(previously presented)*** A compound according to claim 22, wherein

R is H,

$R^1$ is H, A, OA or Hal,

$R^4$ is Ar, cycloalkyl or Het, and

Z is absent.

27. ***(previously presented)*** A compound according to claim 22, wherein

R is H,

$R^1$ is H, A, OA or Hal,

$R^4$ is Het,

Y is absent, and

Z is absent.

28. ***(previously presented)*** A compound according to claim 22, wherein

R is H,

$R^1$ is H, A, OA or Hal, and

Z is phenylene.

29. ***(currently amended)*** A compound of formula Iv



**Iv**

in which

R and $R^1$ are, independently of each other, H, A, OH, OA, $OCH_2$-Ar, Hal, $NH_2$, NHA, $NA_2$, $NO_2$, CN, $C(O)R^2$, $CONH_2$, CONHA, $CONA_2$, COOH, COOA or $SO_2A$,

$R^2$ and $R^3$ are, independently of each other, H, A, or $C(=NH)$-$NH_2$,

$R^4$ is Ar, cycloalkyl, phenylalkyl or Het,

Y is absent or is alkenyl having 2 to 4 carbon atoms,

A is unbranched or branched alkyl having 1 to 6 carbon atoms,

Ar is phenyl, naphthyl, biphenyl or benzofuranyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, $CF_3$, $OCF_3$, Hal, CN, COOH, COOA, $NH_2$, NHA, $NA_2$, $NO_2$, $SO_2NH_2$, $SO_2NAH$ or $SO_2NA_2$,

Het is a saturated, partially or completely unsaturated mono- or bicyclic heterocyclic radical having 5 to 10 ring members, and having 1 or 2 N and/or 1 or 2 S or O atoms, which is optionally mono- or disubstituted by A, Hal, OH, OA, $CF_3$, $OCF_3$, $NH_2$, NHA, $NA_2$, COOH, COOA, phenyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, $CF_3$, $OCF_3$, Hal, CN, COOH, COOA, $NH_2$, NHA, $NA_2$, $NO_2$, $SO_2NH_2$, $SO_2NAH$ or $SO_2NA_2$, ~~or~~ thiophenyl**, or bithiophenyl,** which **latter two groups are** ~~is~~ unsubstituted or mono-, di- or trisubstituted by A, OH, OA, $CF_3$, $OCF_3$, Hal, CN, COOH, COOA, $NH_2$, NHA, $NA_2$, $NO_2$, $SO_2NH_2$, $SO_2NAH$ or $SO_2NA_2$,

Hal is F, Cl, Br or I,

n is 1, 2 or 3, and

m is 0, 1,2 or 3,

or a pharmaceutically acceptable salt or solvate thereof.

30. ***(previously presented)*** A compound according to claim 29, wherein

R is H,

$R^1$ is H, A, OA or Hal, and

Y is alkenyl having 2 to 4 carbon atoms.

31. ***(previously presented)*** A method of antagonizing glycoprotein IbIX comprising administering to a patient in need thereof an effective amount of a compound according to claim 22, or a pharmaceutically acceptable salt or solvate thereof.

32. ***(previously presented)*** A method of controlling a thrombotic disorder and sequelae deriving therefrom, comprising administering to a patient in need thereof an effective amount of a compound according to claim 22, or a pharmaceutically acceptable salt or solvate thereof.

33. ***(previously presented)*** A pharmaceutical composition comprising a compound according to Claim 22 or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable excipient.

34. ***(previously presented)*** A method for the prophylaxis and/or therapy of a thrombotic disorder comprising administering to a patient in need thereof an effective amount of a compound according to claim 22, or a pharmaceutically acceptable salt or solvate thereof.

35. ***(previously presented)*** A method according to claim 32, wherein the sequelae is myocardial infarct, arteriosclerosis, angina pectoris, acute coronary syndrome,

peripheral circulatory disorder, stroke, transient ischaemic attack, or reocclusion/restenosis after angioplasty/stent implantation.

36. ***(previously presented)*** A method of preventing adhesion of substances to a foreign surface inside a body comprising applying a compound according to claim 22 onto said foreign surface.

37. ***(previously presented)*** A method according to claim 36, wherein the foreign surface is an implant, catheter or heart pacemaker.

38. ***(previously presented)*** A method of antagonizing glycoprotein IbIX comprising administering to a patient in need thereof an effective amount of a compound according to claim 29, or a pharmaceutically acceptable salt or solvate thereof.

39. ***(previously presented)*** A method of controlling a thrombotic disorder and sequelae deriving therefrom, comprising administering to a patient in need thereof an effective amount of a compound according to claim 29, or a pharmaceutically acceptable salt or solvate thereof.

40. ***(previously presented)*** A pharmaceutical composition comprising a compound according to Claim 29 or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable excipient.

41. ***(previously presented)*** A method for the prophylaxis and/or therapy of a thrombotic disorder comprising administering to a patient in need thereof an effective amount of a compound according to claim 29, or a pharmaceutically acceptable salt or solvate thereof.

42. ***(previously presented)*** A method according to claim 39, wherein the sequelae is myocardial infarct, arteriosclerosis, angina pectoris, acute coronary syndrome,

peripheral circulatory disorder, stroke, transient ischaemic attack, or reocclusion/restenosis after angioplasty/stent implantation.

43. ***(previously presented)*** A method of preventing adhesion of substances to a foreign surface inside a body comprising applying a compound according to claim 29 onto said foreign surface.

44. ***(previously presented)*** A method according to claim 43, wherein the foreign surface is an implant, catheter or heart pacemaker.

45. ***(previously presented)*** A method of antagonizing glycoprotein IbIX comprising administering to a patient in need thereof an effective amount of a compound according to claim 2, or a pharmaceutically acceptable salt or solvate thereof.

46. ***(previously presented)*** A method of controlling a thrombotic disorder and sequelae deriving therefrom, comprising administering to a patient in need thereof an effective amount of a compound according to claim 2, or a pharmaceutically acceptable salt or solvate thereof.

47. ***(previously presented)*** A pharmaceutical composition comprising a compound according to Claim 2 or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable excipient.

48. ***(previously presented)*** A method for the prophylaxis and/or therapy of a thrombotic disorder comprising administering to a patient in need thereof an effective amount of a compound according to claim 2, or a pharmaceutically acceptable salt or solvate thereof.

49. ***(previously presented)*** A method according to claim 46, wherein the sequelae is myocardial infarct, arteriosclerosis, angina pectoris, acute coronary syndrome,

peripheral circulatory disorder, stroke, transient ischaemic attack, or reocclusion/restenosis after angioplasty/stent implantation.

50. ***(currently amended)*** A method of preventing adhesion of substances to a foreign surface **where said foreign surface comes into contact with a body,** ~~**inside a body**~~ comprising ~~**applying**~~ **the step of preparing a foreign surface comprising** a compound according to claim 2~~ **onto said foreign surface**~~.

51. ***(currently amended)*** A method according to claim **50** ~~**49**~~, wherein the foreign surface is an implant, catheter or heart pacemaker.

52. ***(currently amended)*** A compound of formula I



I

in which

R and $R^1$ are, independently of each other, H, A, OH, OA, $OCH_2$-Ar, Hal, $NH_2$, NHA, $NA_2$, $NO_2$, CN, $C(O)R^2$, $CONH_2$, CONHA, $CONA_2$, COOH, COOA or $SO_2A$,

$R^2$ and $R^3$ are, independently of each other, H, A, or $C(=NH)-NH_2$,

$R^4$ is Ar, cycloalkyl, phenylalkyl or Het,

Y is absent or is alkenyl having 2 to 4 carbon atoms,

Z is absent or is phenylene,

A is, in each case independently, methyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, or 1,1,2- or 1,2,2-trimethylpropyl,

Ar is phenyl, naphthyl, biphenyl or benzofuranyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, $CF_3$, $OCF_3$, Hal, CN, COOH, COOA, $NH_2$, NHA, $NA_2$, $NO_2$, $SO_2NH_2$, $SO_2NAH$ or $SO_2NA_2$,

Het is a saturated, partially or completely unsaturated mono- or bicyclic heterocyclic radical having 5 to 10 ring members, and having 1 or 2 N and/or 1 or 2 S or O atoms, which is optionally mono- or disubstituted by A, Hal, OH, OA, $CF_3$, $OCF_3$, $NH_2$, NHA, $NA_2$, COOH, COOA, phenyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, $CF_3$, $OCF_3$, Hal, CN, COOH, COOA, $NH_2$, NHA, $NA_2$, $NO_2$, $SO_2NH_2$, $SO_2NAH$ or $SO_2NA_2$, ~~or~~ thiophenyl**, or bithiophenyl,** which **latter two groups are** ~~is~~ unsubstituted or mono-, di- or trisubstituted by A, OH, OA, $CF_3$, $OCF_3$, Hal, CN, COOH, COOA, $NH_2$, NHA, $NA_2$, $NO_2$, $S0_2NH_2$, $SO_2NAH$ or $SO_2NA_2$,

Hal is F, Cl, Br or I,

n is 1,2 or 3, and

m is 0, 1,2 or 3,

with the proviso that

if Y is vinyl, $R^4$ is phenyl, Z is absent, n is 1, m is 1 and $R^2$ and $R^3$ are ethyl, then R or $R^1$ is not $NH_2$,

if Z is absent, Y is absent or vinyl, $R^4$ is phenyl, phenylalkyl, alkoxyphenyl or pyridyl, R is H and $R^1$ is **H or** $NH_2$, then $R^2$ and $R^3$ are not A,

**if Z and Y are absent, $R^4$ is phenyl or 4-methoxyphenyl, R, $R^1$, $R^2$ and $R^3$ are H, then the sum of n and m is not 2 or 3,** and

if Z and Y are absent, then $R^4$ is not phenylalkyl,

or a pharmaceutically acceptable salt or solvate thereof.

53. ***(currently amended)*** A compound according to claim **52** ~~51~~ wherein

A is, in each case independently, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1-or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, or 1,1,2- or 1,2,2-trimethylpropyl.

54. ***(currently amended)*** A compound according to claim **52** ~~**51**~~ with the additional provisos that

if Z and Y are absent and $R^4$ is phenyl or 4-methoxyphenyl, then R is not H or 6-Cl, $R^1$ is not H or 8-Cl, $R^2$ is not H, methyl or ethyl, $R^3$ is not H, methyl or ethyl and the sum of n and m is not 2 or 3~~, and~~

~~if Z and Y are absent, R is phenyl or 4-methoxyphenyl, R, R , R and R are H, then the sum of n and m is not 2 or 3~~.

55. ***(currently amended)*** A method of antagonizing glycoprotein IbIX comprising administering to a patient in need thereof an effective amount of a compound according to claim **52** ~~**51**~~, or a pharmaceutically acceptable salt or solvate thereof.

56. ***(currently amended)*** A method of controlling a thrombotic disorder and sequelae deriving therefrom, comprising administering to a patient in need thereof an effective amount of a compound according to claim **52** ~~**51**~~, or a pharmaceutically acceptable salt or solvate thereof.

57. ***(currently amended)*** A pharmaceutical composition comprising a compound according to **claim 52** ~~**Claim 51**~~ or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable excipient.

58. ***(currently amended)*** A method for the prophylaxis and/or therapy of a thrombotic disorder comprising administering to a patient in need thereof an effective amount of a compound according to claim **52** ~~**51**~~, or a pharmaceutically acceptable salt or solvate thereof.

59. ***(currently amended)*** A method according to claim **58** ~~**57**~~, wherein the sequelae is myocardial infarct, arteriosclerosis, angina pectoris, acute coronary syndrome, peripheral circulatory disorder, stroke, transient ischaemic attack, or reocclusion/restenosis after angioplasty/stent implantation.

60. ***(currently amended)*** A method of preventing adhesion of substances to a foreign surface **where said foreign surface comes into contact with a body,** ~~**inside a body**~~ comprising ~~**applying**~~ **the step of preparing a foreign surface comprising** a compound according to claim **52** ~~**51 onto said foreign surface**~~.

61. ***(currently amended)*** A method according to claim **60** ~~**59**~~, wherein the foreign surface is an implant, catheter or heart pacemaker.

62. ***(cancelled)***

63. ***(cancelled)***

64. ***(cancelled)***

65. ***(cancelled)***

66. ***(previously presented)*** A foreign surface having attached thereto a compound according to claim 4.

67. ***(currently amended)*** A foreign surface according to claim **66** ~~**65,**~~ **wherein said foreign surface** ~~**that**~~ is an implant, catheter or heart pacemaker.

68. ***(previously presented)*** A foreign surface having attached thereto a compound according to claim 22.

69. ***(currently amended)*** A foreign surface according to claim **68** ~~**67**~~ **, wherein said foreign surface** ~~**that**~~ is an implant, catheter or heart pacemaker.

70. ***(previously presented)*** A foreign surface having attached thereto a compound according to claim 29.

71. ***(currently amended)*** A foreign surface according to claim **70** ~~**69**~~**, wherein said foreign surface** ~~**that**~~ is an implant, catheter or heart pacemaker.

72. ***(currently amended)*** A foreign surface having attached thereto a compound according to claim **52** ~~**51**~~.

73. ***(currently amended)*** A foreign surface according to claim **72** ~~**71**~~**, wherein said foreign surface** ~~**that**~~ is an implant, catheter or heart pacemaker.